Pacific Biosciences Of California (PACB) Return on Sales (2010 - 2026)

Pacific Biosciences Of California's Return on Sales history runs 17 years deep, the most recent figure standing at 0.0% for Q1 2026.

• On a quarterly basis, Return on Sales rose 11.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a 4.0% increase from a year earlier, with the FY2025 full-year figure at 0.03%, down 1.0% from the prior year.
• Return on Sales advanced to 0.0% in Q1 2026 per PACB's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q4 2024 and bottomed at 0.11% in Q1 2025.
• The 5-year median for Return on Sales is 0.02% (2024), against an average of 0.02%.
• Across the five-year window, Return on Sales retreated 9 bps in 2025 and increased 11 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.03% in 2022, then jumped by 54 bps to 0.01% in 2023, then surged by 104 bps to 0.0% in 2024, then tumbled by 1596 bps to 0.01% in 2025, then jumped by 75 bps to 0.0% in 2026.
• Per Business Quant, the three latest PACB Return on Sales figures stand at 0.0% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).